
CSPC Pharmaceutical Group (1093)
8.45 HKD -0.47 (-5.27%) Volume: 237.01M
CSPC Pharmaceutical Group’s stock price stands at 8.45 HKD, experiencing a dip of -5.27% this trading session, with a substantial trading volume of 237.01M. Despite the recent dip, the stock demonstrates a strong performance with a year-to-date increase of +86.61%.
Latest developments on CSPC Pharmaceutical Group
Today, CSPC Pharmaceutical Group Limited (CVGU) stock experienced high volatility as news broke about JSKN003 being granted breakthrough therapy designation in China. This development has changed the investment story for CSPC Pharmaceutical Group (SEHK:1093), leading to questions about the stock’s potential for long-term investing and its impact on shareholder value. Investors are closely monitoring how this breakthrough therapy status will drive CSPC Pharmaceutical Group‘s stock price movement in the coming days.
CSPC Pharmaceutical Group on Smartkarma
Analysts on Smartkarma, including Tina Banerjee, have provided bullish coverage on CSPC Pharmaceutical Group. In a recent report titled “CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals,” Banerjee highlighted the company’s 1H25 revenue drop of 18.5% YoY due to lower finished drug sales. However, future revenue visibility looks promising with upcoming collaborations and expansion into the high-end market. The company aims to secure more licenses and collaborations in the second half of 2025, which could bode well for its revenue growth.
In another report by Tina Banerjee on Smartkarma, titled “CSPC Pharmaceutical (1093 HK): Finished Drugs Drag 1Q25; Out Licensing And New Launches To Be Key,” the analyst noted a 22% YoY revenue drop in 1Q25 for CSPC Pharmaceutical Group. Despite this, the operating margin remained stable, and the company is focusing on out-licensing and new launches to drive future revenue growth. With a strategic emphasis on license and collaboration deals for pipeline products, CSPC Pharmaceutical aims to enhance its revenue visibility and expand its market presence.
A look at CSPC Pharmaceutical Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a promising long-term outlook. With a high score in dividends and resilience, the company demonstrates a strong ability to generate returns for its investors while also being able to weather market uncertainties. Additionally, CSPC Pharmaceutical Group scores well in momentum and growth, indicating potential for future expansion and positive stock performance.
CSPC Pharmaceutical Group Limited, a company specializing in the manufacturing and sale of pharmaceutical products, has received favorable ratings across various key factors. With a focus on producing vitamin C, antibiotics, and generic drugs, as well as ongoing efforts in developing innovative medications, CSPC Pharmaceutical Group remains well-positioned in the industry. Investors may find value in considering this company for its solid dividend payouts and overall stability in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars